173 related articles for article (PubMed ID: 33826053)
1. Study on the activity of recombinant mutant tissue-type plasminogen activator fused with the C-terminal fragment of hirudin.
Ren K; Gong H; Hu L; He K; Yu A; Hu S; Liang S; Zhou C; Wu C
J Thromb Thrombolysis; 2021 Oct; 52(3):880-888. PubMed ID: 33826053
[TBL] [Abstract][Full Text] [Related]
2. Effect of hirudin on tissue plasminogen activator induced clot lysis.
Electricwala A; Atkinson T
Blood Coagul Fibrinolysis; 1990 Aug; 1(3):267-71. PubMed ID: 2129413
[TBL] [Abstract][Full Text] [Related]
3. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity--a staphylokinase variant. I. In vitro study.
Szemraj J; Walkowiak B; Kawecka I; Janiszewska G; Buczko W; Bartkowiak J; Chabielska E
J Thromb Haemost; 2005 Oct; 3(10):2156-65. PubMed ID: 16150047
[TBL] [Abstract][Full Text] [Related]
4. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
Deschênes I; Finkle CD; Winocour PD
Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.
Mirshahi M; Soria J; Soria C; Faivre R; Lu H; Courtney M; Roitsch C; Tripier D; Caen JP
Blood; 1989 Aug; 74(3):1025-30. PubMed ID: 2502207
[TBL] [Abstract][Full Text] [Related]
6. Fibrin degradation products generation and fibrinopeptide A release in normal plasma incubated with thrombolytic agents: proposed mechanisms.
Mirshahi M; Soria J; Bertrand O; Amiral J; Soria C
Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):531-6. PubMed ID: 1723308
[TBL] [Abstract][Full Text] [Related]
7. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
[TBL] [Abstract][Full Text] [Related]
8. Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir).
Schneider J; Wnendt S; Saunders D; Heinzel-Wieland R; Wilffert B; Steffens G
Eur J Pharmacol; 1996 Apr; 302(1-3):69-77. PubMed ID: 8790994
[TBL] [Abstract][Full Text] [Related]
9. Microfluidic Modeling of Thrombolysis.
Loyau S; Ho-Tin-Noé B; Bourrienne MC; Boulaftali Y; Jandrot-Perrus M
Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2626-2637. PubMed ID: 30354249
[TBL] [Abstract][Full Text] [Related]
10. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
[TBL] [Abstract][Full Text] [Related]
11. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
12. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
14. A fusion protein with improved thrombolytic effect and low bleeding risk.
Wang X; Zhang G; Wang L; Zhang Q; Qin Y; Wu C; Yu A
Thromb Haemost; 2009 Dec; 102(6):1194-203. PubMed ID: 19967151
[TBL] [Abstract][Full Text] [Related]
15. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.
Lijnen HR; Wnendt S; Schneider J; Janocha E; Van Hoef B; Collen D; Steffens GJ
Eur J Biochem; 1995 Nov; 234(1):350-7. PubMed ID: 8529664
[TBL] [Abstract][Full Text] [Related]
16. [Profibrinolytic activity of recombinant hirudin?].
Tsakiris DA; Meyer D; Fabbri J; Close P; Marbet GA
Schweiz Med Wochenschr; 1991 Mar; 121(10):338-40. PubMed ID: 2028237
[TBL] [Abstract][Full Text] [Related]
17. [Effect and mechanism of recombinant hirudin on fibrinolysis].
Li M; Zhang RJ; Cao GX; Wan WX; Zhang LF; Jin J
Yao Xue Xue Bao; 2006 Sep; 41(9):814-8. PubMed ID: 17111825
[TBL] [Abstract][Full Text] [Related]
18. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
[TBL] [Abstract][Full Text] [Related]
19. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.
Xu Y; Wu W; Wang L; Chintala M; Plump AS; Ogletree ML; Chen Z
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):332-8. PubMed ID: 23348428
[TBL] [Abstract][Full Text] [Related]
20. Design and evaluation of a thrombin-activable plasminogen activator.
Yang WP; Goldstein J; Procyk R; Matsueda GR; Shaw SY
Biochemistry; 1994 Mar; 33(8):p606-12. PubMed ID: 8117652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
